Skip to Content

RAS/RAF Targeted Gene Panel by Next Generation Sequencing, Tumor [A Test in Focus]

 
The new RAS/RAF Targeted Gene Panel by Next Generation Sequencing, Tumor, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered to identify:

  • Tumors that may respond to targeted therapies by assessing multiple gene targets simultaneously
  • Mutations that may help determine prognosis for patients with solid tumors
  • Specific mutations within genes known to be associated with response or resistance to specific cancer therapies

 

testinfocus-test-info
testinfocus-highlights-icon
  • This test uses targeted next generation sequencing to evaluate for somatic mutations within the BRAF, HRAS, NRAS, and KRAS genes associated with cancer.
  • Next generation sequencing has recently emerged as an accurate, cost-effective method to identify gene mutations known to be associated with response or resistance to specific targeted therapies.
  • Targeted cancer therapies are antibody or small molecule drugs that block the growth and spread of cancer by interfering with specific cell molecules involved in tumor growth and progression.
testinfocus-testutilization

How to Use This Test

  • To assist in drug selection for patients with solid tumors by identifying specific mutations within genes known to be associated with response or resistance to specific cancer therapies
  • To simultaneously assess multiple genes of the EGFR pathway
  • To determine prognosis for patients with solid tumors
testinfocus-pearls
  • Targeted therapies directed to EGFR, which inhibit activation of the RAS/MAPK pathway, have demonstrated some success with increased progression-free and overall survival in patients with colorectal cancer.
  • Assessment for BRAF mutations has clinical utility in that it is a predictor of response to anti-BRAF therapy and anti-MEK therapy in melanoma.
  • Effectiveness of targeted therapies depends in part on the mutation status of the pathway components.
testinfocus-methodname
  •  PCR-Based Next Generation Sequencing
testinfocus-specimen
  • Preferred: Tissue Block
  • Acceptable: Tissue Slides
testinfocus-performance

Day(s) and Time(s) Test Performed:

  • Performed weekly; Varies

Analytic Time:

  • 12 days
brentwestra

brentwestra

Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.